Caris Life Sciences Inc (CAI) reported financial results for the third quarter of fiscal 2025 that surpassed analyst expectations. The company's earnings per share (EPS) reached $0.08, significantly exceeding the consensus estimate of $-0.21 by $0.29. Revenue matched expectations at $0.2 billion.
The announcement highlights the company's operational performance amid a challenging market. Caris Life Sciences, headquartered in Irving, Texas, provides diagnostics and anatomic pathology services, focusing on precision medicine solutions primarily for oncology. The firm leverages advanced technologies, including next-generation sequencing (NGS) and artificial intelligence (AI), to transform healthcare.
Caris Life Sciences will host an earnings conference call after market close to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's results and future outlook.
As of November 8, 2025, Caris Life Sciences has a market capitalization of $7,225.78 million and a trailing twelve-month EPS of $-1.64. The next earnings report is scheduled for November 4, 2025, with analysts estimating an EPS of $-0.2121 and revenue of $0.2 billion.